Monopar Posts Positive Phase 3 Wilson Disease Data, Plans Mid-2026 NDA

Key Facts

1Monopar's ALXN1840 showed significant neurologic and global clinical improvements versus standard of care in a Phase 3 trial for Wilson disease, with plans to submit an NDA to the FDA in mid-2026.

In a development that bolsters hope for rare disease treatment, Monopar Therapeutics (MNPR) announced new analyses from the Phase 3 FoCus trial of ALXN1840 for Wilson disease. According to the announcement, the drug showed significant neurologic and global clinical improvements versus standard of care, with a favorable safety profile across 266 patients. The company plans to submit a New Drug Application (NDA) to the FDA in mid-2026.

Wilson disease is a rare genetic disorder causing copper accumulation, affecting the liver and nervous system. These positive results follow years of research for alternatives to current therapy, which has tolerability and efficacy limitations. Monopar has not disclosed target market size, but analysts note that a new approved treatment could see strong demand given the scarcity of options.

MNPR closed at $87.68 on June 26, 2026, trading in a range of $85.70 to $92.26 during the session. Investors are now focused on regulatory milestones: the mid-2026 NDA submission is a key catalyst, followed by a potential FDA priority review. The stock may also see volatility from any future trial data updates or approvals from other regulators.